Vasomotor symptoms

Papers on vasomotor symptoms

629 papers51 new in 30 days

Wednesday, November 18

Tuesday, November 17

Sunday, November 15

Wednesday, November 11

Tuesday, November 10

Monday, November 9

Saturday, November 7

Thursday, November 5

Wednesday, November 4

PsyArXiv

Anxiety symptoms linked to hot flash severity around menopause

Two observational studies of 227 and 116 women linked anxiety-specific symptoms, but not depression-specific symptoms, to hot flash severity after accounting for general…Two observational studies of 227 and 116 women linked anxiety-specific symptoms, but not depression-specific symptoms, to hot flash severity after accounting for general distress.

Upright women in dark blue-green have dense heat ripples and chest flutters, while nearby gray women have fewer ripples and flutters.
Preprint: cross-sectional study of 227 peopleAnxiety symptoms

Tuesday, November 3

Monday, November 2

Friday, October 30

Thursday, October 29

Wednesday, October 28

Tuesday, October 27

Obstetrics and Gynecology

Women showed two patterns of hormone decline near menopause

Median hormone decline was 1.2 versus 6.7 picograms per milliliter per month in women with lower versus higher starting levels.Median hormone decline was 1.2 versus 6.7 picograms per milliliter per month in women with lower versus higher starting levels.

Ovarian cross-sections sit among sparse gray and dense blue hormone specks, with a dark heart beside the sparse group and a lighter heart beside the dense…
Cohort · 1,131 peopleMenopause

Monday, October 26

ESC Congress 2026 Abstract

Premenstrual disorders were not linked to midlife artery disease

A cross-sectional study of 4,405 women aged 50 to 64 found no link between premenstrual disorders and artery plaque or heart disease.A cross-sectional study of 4,405 women aged 50 to 64 found no link between premenstrual disorders and artery plaque or heart disease.

Opened artery segments with similarly proportioned plaque deposits sit beside separate groups of upright, faceless women.
Cross-sectional · 4,405 peoplePopulations

Sunday, October 25

EClinicalMedicine

Elinzanetant’s safety profile appeared favorable in women

Over 12 weeks, new or worsening health problems occurred in 50.8% of women taking elinzanetant and 43.2% taking placebo.Over 12 weeks, new or worsening health problems occurred in 50.8% of women taking elinzanetant and 43.2% taking placebo.

Study design. aFor SWITCH-1, elinzanetant 40 mg, 80 mg, and 160 mg were excluded from the pooled safety analysis.
Meta-analysis · 1,519 peopleElinzanetant

Friday, October 23